X

Trial Profile

A Pivotal trial of biosimilar insulin glargine

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 11 Jan 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin glargine (Primary)
Indications Diabetes mellitus
Focus Pharmacodynamics; Pharmacokinetics; Registrational
Sponsors Lannett

Most Recent Events

04 Jan 2023 According to a Lannett media release, filing the BLA for biosimilar insulin glargine will be pushed back by about two months to mid-year 2023 but potential launch timing remains in range.
02 Nov 2022 According to a Lannett media release, initial results from the trial are expected in December 2022.
31 Aug 2022 Status changed from recruiting to active, no longer recruiting, according to a Lannett media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com